Behradmanesh S, Ranjbar Omrani Gh H, Ghazanfarpour F, Baradaran A
Department of Internal Medicine and Endocrinology, Shahr-e-Kord University of Medical Sciences, Shahr-e-Kord, Iran.
Iran Red Crescent Med J. 2011 Jul;13(7):487-92. Epub 2011 Jul 1.
Polycystic ovary syndrome (PCOS) is one of the most common diseases among women associat-ed with various inflammatory reactants such as C-reactive protein (CRP) and ferritin. This study aimed to investi-gate the effect of metformin on probable reduction of serum ferritin in patients with PCOS.
This study was conducted on 45 patients with PCOS who had not other systemic diseases and did not take any medications. Weight, waist and hip circumstances (WHR), body mass index (BMI), metabolic indexes, CRP, ferritin and "Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) ˝ were measured before the study. Metformin (500 mg/tid) tablets were prescribed for three months and then same above parameters were re-measured.
Of 45 patients, 19 (42.2%) were overweight and 14 (31.1%) were obese. After drug therapy, there was a significant reduction in waist circumstance and serum ferritin. This reduction was significant only in the lean and overweight groups but not in the obese group. There was not significant association between serum ferritin and CRP, HOMA-IR, BMI and WHR. There was not significant correlation between CRP and HOMA-IR and also BMI.
The effect of metformin on reduction of serum ferritin was not significant just in obese group and was not associated with metabolic and anthropometric indexes.
多囊卵巢综合征（PCOS）是女性中最常见的疾病之一，与多种炎症反应物如C反应蛋白（CRP）和铁蛋白有关。本研究旨在探讨二甲双胍对降低PCOS患者血清铁蛋白的作用。
本研究对45例无其他全身性疾病且未服用任何药物的PCOS患者进行。在研究前测量体重、腰围和臀围（腰臀比）、体重指数（BMI）、代谢指标、CRP、铁蛋白和“胰岛素抵抗稳态模型评估（HOMA-IR）”。给予二甲双胍（500毫克/每日三次）片剂服用三个月，然后重新测量上述相同参数。
45例患者中，19例（42.2%）超重，14例（31.1%）肥胖。药物治疗后，腰围和血清铁蛋白显著降低。这种降低仅在瘦型和超重组中显著，而在肥胖组中不显著。血清铁蛋白与CRP、HOMA-IR、BMI和腰臀比之间无显著关联。CRP与HOMA-IR以及BMI之间也无显著相关性。
二甲双胍降低血清铁蛋白的作用仅在肥胖组中不显著，且与代谢和人体测量指标无关。
